ETHINYL ESTRADIOL; NORETHINDRONE - Generic Drug Details

What are the generic drug sources for ethinyl estradiol; norethindrone and what is the scope of freedom to operate?

Ethinyl estradiol; norethindrone is the generic ingredient in one hundred and eighteen branded drugs marketed by Lupin Ltd, Teva Branded Pharm, Xiromed, Apil, Aurobindo Pharma, Amneal Pharms, Barr, Naari Pte, Allergan, Ortho Mcneil Pharm, LPI, Watson Pharms Teva, Watson Labs, Watson Labs Teva, Ortho Mcneil Janssen, Janssen Pharms, Warner Chilcott, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Ph Health, Novast Labs Ltd, Barr Labs, Mylan Labs Ltd, Warner Chilcott Llc, Wilshire Pharms Inc, Millicent Pr, Teva Pharms Usa Inc, Novast Labs, Lupin, Barr Labs Inc, Apotex, Glenmark Speclt, and Parke Davis, and is included in one hundred and fifty NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ETHINYL ESTRADIOL; NORETHINDRONE

US Patents:	2
Tradenames:	118
Applicants:	33
NDAs:	150
Finished Product Suppliers / Packagers:	15
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	44
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ETHINYL ESTRADIOL; NORETHINDRONE
DailyMed Link:	ETHINYL ESTRADIOL; NORETHINDRONE at DailyMed

Recent Clinical Trials for ETHINYL ESTRADIOL; NORETHINDRONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vertex Pharmaceuticals Incorporated	PHASE1
Cairo University	PHASE3
ViiV Healthcare	PHASE1

See all ETHINYL ESTRADIOL; NORETHINDRONE clinical trials

Generic filers with tentative approvals for ETHINYL ESTRADIOL; NORETHINDRONE

Applicant	Application No.	Strength	Dosage Form
		0.01MG,0.01MG;1MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ETHINYL ESTRADIOL; NORETHINDRONE

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ETHINYL ESTRADIOL; NORETHINDRONE

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for ETHINYL ESTRADIOL; NORETHINDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs Ltd	DASETTA 7/7/7	ethinyl estradiol; norethindrone	TABLET;ORAL-28	090946-001	Dec 22, 2011	AB	RX	No	Yes
Ph Health	GILDESS FE 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	077075-001	Apr 28, 2005		DISCN	No	No
Watson Labs	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)	ethinyl estradiol; norethindrone	TABLET;ORAL-21	071043-001	Apr 1, 1988		DISCN	No	No
Novast Labs	LARIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	202994-001	Feb 18, 2015	AB	RX	No	No
Watson Labs	NORETHINDRONE AND ETHINYL ESTRADIOL	ethinyl estradiol; norethindrone	TABLET;ORAL-28	076393-001	Feb 4, 2010		DISCN	No	No

Expired US Patents for ETHINYL ESTRADIOL; NORETHINDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	ORTHO-NOVUM 7/7/7-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018985-002	Apr 4, 1984	4,628,051
Teva Branded Pharm	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone	TABLET, CHEWABLE;ORAL	022573-001	Dec 22, 2010	5,552,394
Janssen Pharms	ORTHO-NOVUM 7/7/7-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018985-002	Apr 4, 1984	4,544,554
Dr Reddys Labs Sa	TRI-NORINYL 28-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018977-002	Apr 13, 1984	4,390,531
Janssen Pharms	ORTHO-NOVUM 7/7/7-21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	018985-001	Apr 4, 1984	4,616,006

Market Overview and Financial Trajectory for Ethinyl Estradiol; Norethindrone

Last updated: February 14, 2026

The combination of Ethinyl Estradiol and Norethindrone is a widely used oral contraceptive formulation. It plays a significant role in the global hormonal contraceptives market, with steady demand driven by contraceptive needs, treatment of hormonal imbalances, and therapeutic indications. The market dynamics reflect the regulatory environment, patent landscape, manufacturing capacity, and competitive positioning.

Market Size and Growth Trends

The global hormonal contraceptives market was valued at approximately USD 6.5 billion in 2022 and is projected to reach USD 8.2 billion by 2027, growing at a compound annual growth rate (CAGR) of about 4.4% [1]. Ethinyl Estradiol; Norethindrone products account for roughly 30-35% of this market segment, with the remainder contributed by other combination pills and solo formulations.

Key factors influencing growth:

• Rising global awareness of family planning.
• Increasing use among adolescents and women of reproductive age.
• Expanding approval for therapeutic indications beyond contraception, such as hormonal regulation.

The U.S. remains the largest market, followed by Europe and Asia-Pacific. Emerging markets are experiencing faster growth due to increased healthcare access.

Regulatory and Patent Landscape

Patents for Ethinyl Estradiol; Norethindrone formulations have mostly expired or are nearing expiration, leading to market entry by generics. Major patented products included Merck's "Ortho-Novum" and Teva’s "Norethindrone" formulations. The generic landscape enhances price competition, with average prices for a pack decreasing by 10-15% annually in some regions [2].

Regulatory approvals by agencies such as the FDA, EMA, and China's NMPA facilitate market access. Recent approvals for new formulations with improved safety profiles have contributed to market expansion. However, regulatory barriers for new fixed-dose combinations (FDCs) persist, especially regarding safety and efficacy data.

Competitive Dynamics

Market players:

• Largest brands: Pfizer, Teva, Mylan (now part of Viatris), and Sandoz.
• Key generic manufacturers capitalize on patent expiries.
• Generic penetration accounts for over 60% in developed markets.

Price competition influences market share, with generics offering discounts of 20-30% over branded products. Innovative formulations with reduced side effects or alternative dosing schedules are emerging, targeting consumer preferences.

Manufacturing and Supply Chain Factors

Major manufacturing hubs include India, China, and Europe. Supply chain disruptions due to geopolitical tensions and COVID-19 have temporarily affected production and distribution.

Quality standards and regulatory compliance are critical. Companies investing in manufacturing capacity upgrades and compliance are better positioned to capitalize on expanding markets.

Financial Trajectory and Investment Outlook

The steady demand and patent expiries support a predictable revenue stream for established manufacturers. The introduction of biosimilar and combination products with novel delivery systems (e.g., transdermal patches, implants) could diversify revenue.

Investments are targeted toward:

• Formulation innovation.
• Expanding into emerging markets.
• Enhancing safety profiles through clinical development.

Market forecasts project a compound annual growth rate (CAGR) of around 3-5% for Ethinyl Estradiol; Norethindrone products over the next five years.

Challenges and Risks

• Regulatory hurdles for new formulations.
• Patent litigation and market access barriers.
• Competition from other hormonal formulations specified for specific patient populations.
• Cultural, religious, and social factors impacting acceptance.

---

Key Takeaways

• The Ethinyl Estradiol; Norethindrone market is driven by global demographic trends and contraceptive needs.
• Patent expiries are fostering price competition and generic market expansion.
• The market faces regulatory and supply chain challenges that could influence growth.
• Innovations in formulation and delivery mechanisms are strategic for maintaining competitiveness.
• The expected CAGR remains between 3-5%, with emerging markets offering significant growth potential.

---

FAQs

1. What are the key competitors in the Ethinyl Estradiol; Norethindrone market?
   Major brands from Pfizer, Teva, Mitsubishi Tanabe Pharma, and Viatris dominate, alongside numerous generics from Indian and Chinese manufacturers.

2. How do patent expiries influence market dynamics?
   They enable generic manufacturers to enter the market, reducing prices and increasing accessibility, which accelerates market volume but reduces profit margins for originators.

3. What are the main therapeutic uses beyond contraception?
   Treatment of hormonal imbalance, endometriosis, and menstrual disorders.

4. Are there safety concerns impacting the market?
   Yes; risks linked to blood clots, stroke, and other side effects influence regulatory scrutiny and shape product development.

5. What innovations are emerging in this market?
   Fixed-dose combinations with lower hormone doses, transdermal patches, subcutaneous implants, and novel delivery systems aim to improve safety, compliance, and user experience.

---

References

[1] MarketWatch, "Hormonal Contraceptives Market Size, Share & Trends Analysis," 2022.
[2] IQVIA, "Global generic drug pricing trends," 2022.